Acknowledgement
The authors thank all their coworkers involved in the study for their support and assistance.
References
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48
- Kudo S, Imai K, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. New CT criteria for nodal staging in non-small cell lung cancer. Clin Imaging 2014;38:448-453
- Xia Y, Zhang B, Zhang H, Li W, Wang KP, Shen H. Evaluation of lymph node metastasis in lung cancer: who is the chief justice? J Thorac Dis 2015;7(Suppl 4):S231-S237
- Liao X, Liu M, Li S, Huang W, Guo C, Liu J, et al. The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer. BMC Med Imaging 2023;23:49
- Marcus C, Tajmir SH, Rowe SP, Sheikhbahaei S, Solnes LB. 18F-FDG PET/CT for response assessment in lung cancer. Semin Nucl Med 2022;52:662-672
- Sun Y, Xiao L, Wang Y, Liu C, Cao L, Zhai W, et al. Diagnostic value of dynamic 18F-FDG PET/CT imaging in non-small cell lung cancer and FDG hypermetabolic lymph nodes. Quant Imaging Med Surg 2023;13:2556-2567
- Bille A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009;36:440-445
- Xiao L, Xin J. Advances in clinical oncology research on 99mTc-3PRGD2 SPECT imaging. Front Oncol 2022;12:898764
- Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006;312:651-658
- Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 2011;1:30-47
- Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, et al. 99mTc3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med 2012;53:716-722
- Chen Z, Fu F, Li F, Zhu Z, Yang Y, Chen X, et al. Comparison of [99mTc]3PRGD2 imaging and [18F]FDG PET/CT in breast cancer and expression of integrin αvβ3 in breast cancer vascular endothelial cells. Mol Imaging Biol 2018;20:846-856
- Zheng S, Chen Z, Huang C, Chen Y, Miao W. [99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT. Ann Nucl Med 2019;33:135-143
- Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, et al. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer. Radiology 2016;281:958-966
- Lv N, Gao S, Bai L, Ji B, Xue J, Ge X, et al. Advantages of 99mTc-3PRGD2 SPECT over CT in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Ann Nucl Med 2019;33:39-46
- Watanabe S. Lymph node dissection for lung cancer: past, present, and future. Gen Thorac Cardiovasc Surg 2014;62:407-414
- Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin αvβ3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002;19:427-436
- Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B 2021;11:2726-2737
- Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem 2008;51:7980-7990
- Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD 2 in non-human primates. Mol Imaging Biol 2011;13:730-736